Clinical Trials Logo

Motor Neuron Disease clinical trials

View clinical trials related to Motor Neuron Disease.

Filter by:

NCT ID: NCT02242071 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.

NCT ID: NCT02116634 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis

Start date: May 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Whether the mesenchymal injection on ALS patients is effective or not?

NCT ID: NCT01984814 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The effect of autologous bone marrow mononuclear cells on duration of survival in Amyotrophic Lateral Sclerosis patients.

NCT ID: NCT01954875 Withdrawn - Multiple Sclerosis Clinical Trials

Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases

Start date: December 2, 2009
Phase:
Study type: Observational

The etiology of many neurodegenerative diseases is unknown. A few studies have suggested the role of infection in the gastrointestinal tract in the etiology and pathogenesis of neurological diseases such as idiopathic Parkinson. For example, infection with Helicobacter pylori has been suggested to play a role in Parkinson disease. In addition, bacterial pathogens such as spirochetes and bacterial products such as cyanobacterial toxins have been speculated as the contributing factors in the development of amyotrophic lateral sclerosis (ALS). The effect of microbial composition of the gut in the pathogenesis of ALS is suspected. The difference in the bacterial profile of the gut has been documented in diseases such as inflammatory bowel disease and obesity. The goal of this IRB protocol is to create a human tissue bank and to obtain patients' demographic information for future investigation of the role of bacterial pathogens and the role of gut flora composition in the development of neurodegenerative diseases including but not limited to ALS, Parkinson's disease, and multiple sclerosis.

NCT ID: NCT01945853 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)

Start date: July 2013
Phase: N/A
Study type: Interventional

This is a pilot study to identify the degree of grey and white matter involvement in patients with Amyotrophic Lateral Sclerosis (ALS) utilizing non-invasive techniques. The imaging to be utilized will be the 7 Tesla (7T) magnetic resonance imaging (MRI) of the brain. These results will be correlated to the ALS Functional Rating Scale - Revised (ALSFRS-R) score to assess if any changes in MRI can be predictive in the disability of the ALS patients at baseline and at 6 month intervals. The participants will be asked to return every 6 months for a neurological examination, ALSFRS-R assessment, measurement of the vital capacity and MRI as outlined above to monitor progression of the disease.

NCT ID: NCT01565395 Withdrawn - Parkinson Disease Clinical Trials

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Xeomin
Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.

NCT ID: NCT00846560 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

Start date: August 2008
Phase: N/A
Study type: Observational

The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.

NCT ID: NCT00561366 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Start date: n/a
Phase: Phase 2
Study type: Interventional

Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase (SOD1) transgenic mouse model of ALS. Furthermore, it has been demonstrated to have neuroprotective and neuroregenerative effects in other rat models of nerve damage. Molecular chaperone proteins are critical in the cellular response to stress and protein misfolding. Recent data suggest that the SOD1 mutation responsible for ALS in some patients with familial disease reduces the availability of a variety of molecular chaperones, and thus weakens their ability to respond to cellular stress. Protein misfolding and consequent aggregation may play a role in the pathogenesis of both the familial and sporadic forms of ALS. Therapeutic agents such as arimoclomol that improve cellular chaperone response to protein misfolding may be helpful in ALS.